SCHEMBL22982020

SCHEMBL22982020

CC(C)C[C]1C=Cc2cc3ccccc3cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
ELANE P08246 1/20 0.34
UGT2B7 P16662 1/20 0.32
ALDH1A1 P00352 1/20 0.31
TP53 P04637 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
HIF1A Q16665 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22982589 0.83 RIPK1 (0.41)
SCHEMBL22982022 0.79 CYP2A6 (0.41) ALDH1A1TP53HPGDTSHRMAPK1
SCHEMBL22983051 0.77 LMNA (0.38) HTR2AHTR2CHTR2BELANEALDH1A1
SCHEMBL22982410 0.76 RIPK1 (0.33) ALDH1A1TP53HPGDTSHRMAPK1
SCHEMBL22982483 0.76 CYP1A2 (0.34) ALDH1A1TP53HPGDTSHRMAPK1
SCHEMBL29033364 0.76 LMNA (0.36) HTR2AHTR2CHTR2BELANEALDH1A1
SCHEMBL22982006 0.74 TLR8 (0.37) RAB9ASMN1; SMN2
SCHEMBL22982497 0.73 CYP11B1 (0.41) ALDH1A1TP53HPGDTSHRMAPK1
SCHEMBL23273292 0.72 TLR8 (0.39) RAB9ASMN1; SMN2
SCHEMBL22982493 0.72 UGT2B7 (0.38) HTR2AHTR2CHTR2BUGT2B7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661465-B2 Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-05-30 US disclosed
CN-114845980-A Dimer-selective metallocene catalyst, non-aromatic hydrocarbon soluble activator and method for preparing poly alpha-olefin oligomer using the same 埃克森美孚化学专利公司 2022-08-02 CN disclosed
EP-4010385-A1 PROCESS TO PRODUCE LOW VISCOSITY POLYALPHAOLEFINS USING NON-AROMATIC-HYDROCARBON SOLUBLE ACTIVATORS ExxonMobil Chemical Patents Inc. (US) 2022-06-15 EP disclosed
CN-114502521-A Process for producing low viscosity polyalphaolefins using non-aromatic hydrocarbon soluble activators 埃克森美孚化学专利公司 2022-05-13 CN disclosed
WO-2021086926-A1 DIMER SELECTIVE METALLOCENE CATALYSTS, NON-AROMATIC HYDROCARBON SOLUBLE ACTIVATORS, AND PROCESSES TO PRODUCE POLY ALPHA-OLEFIN OLIGMERS THEREWITH EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-05-06 WO disclosed
US-20210122859-A1 Dimer Selective Metallocene Catalysts, Non-Aromatic Hydrocarbon Soluble Activators, And Processes To Produce Poly Alpha-Olefin Oligmers Therewith EXXONMOBIL CHEMICAL PATENTS INC (US) 2021-04-29 US disclosed
WO-2021030045-A1 PROCESS TO PRODUCE LOW VISCOSITY POLYALPHAOLEFINS USING NON-AROMATIC-HYDROCARBON SOLUBLE ACTIVATORS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661465-B2 Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith NONO, TPR, ZNF787 HTR2A 1640/4885HTR2C 1386/4885HTR2B 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.